title: Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies.
abstract: Therapy-related acute myeloid leukemia (t-AML) is a heterogeneous entity most frequently related to breast cancer or lymphoproliferative diseases (LD). Population-based studies have reported an increased risk of t-AML after treatment of lymphomas. The aim of this study was to describe the characteristics and outcome of 80 consecutive cases of t-AML following treatment of LD. t-AML accounted for 2.3% of all AML cases, occurred 60 months after LD diagnosis, and were characterized by a high frequency of FAB M6 AML and poor-risk cytogenetic abnormalities. Time to t-AML diagnosis was influenced by patient age, type of LD, and treatment. Among the 48 t-AML patients treated with intensive chemotherapy, median overall survival (OS) was 7.7 months compared to 26.1 months in de novo, 4.2 months in post-myeloproliferative neoplasm, 9.4 months in post-myelodysplastic syndrome, 8.6 months in post-chronic myelomonocytic leukemia AML, 13.4 months in t-AML secondary to the treatment of solid cancer, and 14.7 months in breast cancer only. OS of post-LD t-AML patients was significantly influenced by age, performance status, myelodysplastic syndrome prior to LD/t-AML, and treatment regimen for LD. Thus, t-AML following lymphoid malignancies treatment should be considered as very high-risk secondary AML. New treatment strategies in patients with LD/t-AML are needed urgently.
authors.affiliation: Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.|Université Toulouse III Paul Sabatier, Toulouse, France.|Cancer Research Center of Toulouse (CRCT), UMR1037 INSERM, ERL5294 CNRS, Toulouse, France.
authors.forename: Sarah
authors.initials: S
authors.lastname: Bertoli
authors.affiliation: Service d'Hématologie, Institut Paoli-Calmettes, Marseille, France.
authors.forename: Arthur
authors.initials: A
authors.lastname: Sterin
authors.affiliation: Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
authors.forename: Suzanne
authors.initials: S
authors.lastname: Tavitian
authors.affiliation: Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
authors.forename: Lucie
authors.initials: L
authors.lastname: Oberic
authors.affiliation: Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.|Université Toulouse III Paul Sabatier, Toulouse, France.|Cancer Research Center of Toulouse (CRCT), UMR1037 INSERM, ERL5294 CNRS, Toulouse, France.
authors.forename: Loïc
authors.initials: L
authors.lastname: Ysebaert
authors.affiliation: Service d'Hématologie, Institut Paoli-Calmettes, Marseille, France.
authors.forename: Reda
authors.initials: R
authors.lastname: Bouabdallah
authors.affiliation: Cancer Research Center of Toulouse (CRCT), UMR1037 INSERM, ERL5294 CNRS, Toulouse, France.|Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
authors.forename: François
authors.initials: F
authors.lastname: Vergez
authors.affiliation: Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
authors.forename: Audrey
authors.initials: A
authors.lastname: Sarry
authors.affiliation: Service d'Epidémiologie, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.|UMR 1027, INSERM-Université de Toulouse III, Toulouse, France.
authors.forename: Emilie
authors.initials: E
authors.lastname: Bérard
authors.affiliation: Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
authors.forename: Françoise
authors.initials: F
authors.lastname: Huguet
authors.affiliation: Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.|Université Toulouse III Paul Sabatier, Toulouse, France.
authors.forename: Guy
authors.initials: G
authors.lastname: Laurent
authors.affiliation: Service d'Hématologie, Institut Paoli-Calmettes, Marseille, France.|Département d'Oncologie Moléculaire, Centre de Recherche en Cancérologie de Marseille (CRCM), Institut Paoli-Calmettes, UMR1068 Inserm, Marseille, France.
authors.forename: Thomas
authors.initials: T
authors.lastname: Prébet
authors.affiliation: Service d'Hématologie, Institut Paoli-Calmettes, Marseille, France.|Département d'Oncologie Moléculaire, Centre de Recherche en Cancérologie de Marseille (CRCM), Institut Paoli-Calmettes, UMR1068 Inserm, Marseille, France.|Aix-Marseille University, Marseille, France.
authors.forename: Norbert
authors.initials: N
authors.lastname: Vey
authors.affiliation: Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.|Université Toulouse III Paul Sabatier, Toulouse, France.|Cancer Research Center of Toulouse (CRCT), UMR1037 INSERM, ERL5294 CNRS, Toulouse, France.
authors.forename: Christian
authors.initials: C
authors.lastname: Récher
mesh_terms: D000368:Aged; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D008232:Lymphoproliferative Disorders / Q000628:therapy*; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000188:drug therapy* / Q000401:mortality; D013997:Time Factors
keywords: chronic lymphocytic leukemia; leukemia; lymphoma; second cancer; therapy-related acute myeloid leukemia